Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide [9]

BJU International

Volumn 88, Issue 3, 2001, Pages 306-308

  Yashi, M ^a   Muraishi, O ^a   Tokue, A ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; CHROMOGRANIN A; DIAMINOBENZIDINE; HEMATOXYLIN; IMMUNOGLOBULIN G; MARKER; NEUROPEPTIDE; PEROXIDASE; POLYCLONAL ANTIBODY; PROGASTRIN; PROGASTRIN RELEASING PEPTIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLOOD LEVEL; CANCER GROWTH; CANCER STAGING; CYTOPLASM; DISEASE MARKER; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; LUNG SMALL CELL CANCER; NEUROENDOCRINE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; STANDARD; TECHNIQUE;

EID: 0034819304     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.2310o.x     Document Type: Letter

References (5)

1. Prostatic small-cell neuro-endocrine carcinoma disease progression monitored by measurement of serum progastrin-releasing peptide
2. Clinical significance for diagnosis of serum ProGRP by enzyme-linked immunosorbent assay (ELISA)
3. Histologic variants of adenocarcinoma and other carcinomas of prostate: Pathologic criteria and clinical significance
4. Follow-up in prostate cancer patients: Parameters are necessary?
5. Circulating neuroendocrine markers in patients with prostate carcinoma